Paul Beresford, VP of Bus Dev, Biodesix Bio and Contact Info
Listen (4:47) VeriStrat - a test for non-small cell lung cancer
Listen (4:39) What do you anticipate on the regulatory front?
Listen (6:01) Evolution of the Dx model away from cost plus
Listen (3:39) New legislation
Mass spectrometry has been a valuable research platform for many years. But clinical uptake of the technology has proved illusive. Until now.
In today’s program, Paul Beresford says that his company, Biodesix, out of Boulder, Colorado has been able to improve mass spec to a clinical, commercially viable level. The company already has a proteomics based test on the market, VeriStrat, a predictive and prognostic for non-small cell lung cancer. And this is just the beginning. Announcing a new round of funding this week, the company intends to use the platform for other cancers and tests.
Working for eight years at Ventana Medical Systems before his current stint at Biodesix, Paul offers a seasoned perspective on the challenges facing all diagnostics companies. Asked about how we as an industry can raise the value of diagnostics, Paul says that the “value-based play for diagnostics is actually getting better” and sees help on the horizon from Congress.
“Legislation is moving forward so that these [high value diagnostic] tests will essentially be priced through a market assessment versus Medicare just picking a price,” he says.